Consolidated Financial Results for Fiscal 2016
`
`(Reference Data of Financial Statements for the 2Q of Fiscal 2016)
`
`November 7, 2016
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
` Corporate Communications
` Tel:
` +81-(0)3-5977-5002
` Fax:
` +81-(0)3-5977-5131
` Email:
` koho@kaken.co.jp
`
`Page 1 of 5
`
`ACRUX DDS PTY LTD. et al.
`
`EXHIBIT 1650
`
`IPR Petition for
`
`U.S. Patent No. 7,214,506
`
`

`

`1. Summary of Consolidated Financial Statements for the Second Quarter of Fiscal 2016
`
`FY2015
`2nd Q
`
`FY2015
`
`FY2016
`2nd Q
`
`Y o Y increase (decrease)
`
`Yen
`
`%
`
`FY2016
`Forecasts
`
`Y o Y increase (decrease)
`
`Yen
`
`%
`
`( Figures less than one million yen have been omitted)
`
`Net sales
`
`54,973
`
`109,730
`
`Operating income
`
`18,443
`
`35,146
`
`52,179
`
`16,123
`
`(2,793)
`
`(2,319)
`
`94.9% 106,100
`
`87.4%
`
`28,900
`
`(3,630)
`
`(6,246)
`
`96.7%
`
`82.2%
`
` Ratio of net sales
`
`33.6%
`
`32.0%
`
`30.9%
`
`27.2%
`
`Ordinary income
`
`18,573
`
`35,365
`
`16,238
`
`(2,335)
`
`87.4%
`
`29,100
`
`(6,265)
`
`82.3%
`
` Ratio of net sales
`
`33.8%
`
`32.2%
`
`31.1%
`
`27.4%
`
`Net income
`
`12,483
`
`21,143
`
`11,446
`
`(1,037)
`
`91.7%
`
`20,800
`
`(343)
`
`98.4%
`
` Ratio of net sales
`
`22.7%
`
`19.3%
`
`21.9%
`
`Per share profit (Yen)
`
`301.39
`
`510.54
`
`278.02
`
`19.6%
`
`508.90
`
`Note: Kaken has conducted a consolidation of common share at rate of one share for every two shares with effective date of October 1, 2015.
` Per shar profit has been calculated as if this consolidation of shares was conducted at the bigining of previous fiscal year.
`
`Comprehensive income
`
`11,308
`
`18,444
`
`11,597
`
`288
`
`102.6%
`
`Capital investment
`
`1,529
`
`2,923
`
`861
`
`(668)
`
`56.3%
`
`2,100
`
`(823)
`
`71.8%
`
`R&D expenses
`
`2,965
`
`5,883
`
`3,627
`
`661
`
`122.3%
`
`10,200
`
`4,317
`
`173.4%
`
`Depreciation and amortization
`
`1,039
`
`2,242
`
`903
`
`(135)
`
`86.9%
`
`2,100
`
`(142)
`
`93.7%
`
`Employee number
`
`1,482
`
`1,451
`
`1,443
`
`(39)
`
`2. Breakdown of Consolidated Net Sales by Segment
`
`( Figures less than one million yen have been omitted)
`
`FY2015
`2nd Q
`
`FY2015
`
`FY2016
`2nd Q
`
`Y o Y increase (decrease)
`
`Yen
`
`%
`
`53,794
`
`107,391
`
`50,988
`
`(2,805)
`
`94.8%
`
`Pharmaceuticals,
`medical devices &
`agrochemicals
`
`Real estate
`
`1,178
`
`2,338
`
`1,190
`
`12
`
`101.0%
`
`Total
`
`54,973
`
`109,730
`
`52,179
`
`(2,793)
`
`94.9%
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`1
`
`Page 2 of 5
`
`

`

`3. Summary of Consolidated Balance Sheets
`
`As of
`September 30,
`2015
`
`Ratio
`
`( Figures less than one million yen have been omitted)
`As of
`Y o Y
`March 31,
`increase
`2016
`(decrease)
`
`Ratio
`
`Ratio
`
`As of
`September 30,
`2016
`
`Assets
`
`124,299
`
`100.0%
`
`132,991
`
`100.0%
`
`131,648
`
`100.0%
`
`(1,343)
`
` Current assets
`
` Noncurrent assets
`
`Liabilities
`
` Current liabilities
`
` Noncurrent liabilities
`
`79,022
`
`45,277
`
`38,714
`
`31,727
`
`6,986
`
`63.6%
`
`88,991
`
`66.9%
`
`87,134
`
`36.4%
`
`43,999
`
`33.1%
`
`44,513
`
`31.1%
`
`43,116
`
`32.4%
`
`36,911
`
`25.5%
`
`33,861
`
`25.5%
`
`28,224
`
`5.6%
`
`9,255
`
`7.0%
`
`8,686
`
`Net assets
`
`85,585
`
`68.9%
`
`89,875
`
`67.6%
`
`94,736
`
`19.2%
`
`23,853
`
`17.9%
`
`23,853
`
`66.2%
`
`33.8%
`
`28.0%
`
`21.4%
`
`6.6%
`
`72.0%
`
`18.1%
`
`(1,856)
`
`513
`
`(6,205)
`
`(5,636)
`
`(568)
`
`4,861
`
`－
`
` Capital stock
`
` Capital surplus
`
` Retained earnings
`
`23,853
`
`11,407
`
`62,765
`
`9.2%
`
`11,407
`
`8.6%
`
`11,407
`
`8.7%
`
`－
`
`50.5%
`
`68,609
`
`51.6%
`
`76,826
`
`58.4%
`
`8,217
`
` Treasury stock
`
`(16,271)
`
`(13.1%)
`
`(16,301)
`
`(12.3%)
`
`(19,807)
`
`(15.0%)
`
`(3,506)
`
`Valuation difference on
`available-for-sale securities
`
`Remeasurements of defined
`benefit plans
`
`4,188
`
`3.4%
`
`4,423
`
`3.3%
`
`4,355
`
`3.3%
`
`(68)
`
`(357)
`
`(0.3%)
`
`(2,117)
`
`(1.6%)
`
`(1,897)
`
`(1.4%)
`
`219
`
`4. Summary of Consolidated Statements of Cash Flows
`
`( Figures less than one million yen have been omitted)
`Y o Y
`increase
`(decrease)
`
`FY2015
`2nd Q
`
`FY2015
`
`FY2016
`2nd Q
`
`Net cash provided by (used in) operating activities
`
`10,551
`
`27,067
`
`5,699
`
`(4,851)
`
`Net cash provided by (used in) investing activities
`
`(1,754)
`
`(4,105)
`
`(2,151)
`
`(397)
`
`Net cash provided by (used in) financing activities
`
`(2,821)
`
`(5,984)
`
`(6,729)
`
`(3,908)
`
`Cash and cash equivalents at end of period
`
`30,742
`
`41,744
`
`38,562
`
`7,819
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`2
`
`Page 3 of 5
`
`

`

`5. Summary of Non-consolidated Financial Statements for the Second Quarter of Fiscal 2016
`
`( Figures less than one million yen have been omitted)
`
`FY2015
`2nd Q
`
`FY2015
`
`FY2016
`2nd Q
`
`Y o Y increase(decrease) FY2016
`Forecasts
`
`Yen
`
`%
`
`Y o Y increase(decrease)
`
`Yen
`
`%
`
`Net sales
`
`53,851
`
`107,627
`
`Operating income
`
`18,119
`
`34,468
`
`51,406
`
`16,069
`
`(2,445)
`
`(2,050)
`
`95.5% 104,400
`
`88.7%
`
`28,800
`
`(3,227)
`
`(5,668)
`
`97.0%
`
`83.6%
`
` Ratio of net sales
`
`33.6%
`
`32.0%
`
`31.3%
`
`27.6%
`
`Ordinary income
`
`18,277
`
`34,743
`
`16,183
`
`(2,094)
`
`88.5%
`
`29,000
`
`(5,743)
`
`83.5%
`
` Ratio of net sales
`
`33.9%
`
`32.3%
`
`31.5%
`
`27.8%
`
`Net income
`
`12,295
`
`18,757
`
`11,411
`
`(883)
`
`92.8%
`
`20,700
`
`1,943
`
`110.4%
`
` Ratio of net sales
`
`22.8%
`
`17.4%
`
`22.2%
`
`19.8%
`
`Capital investment
`
`1,508
`
`2,897
`
`861
`
`(647)
`
`57.1%
`
`2,100
`
`(797)
`
`72.5%
`
`R&D expenses
`
`2,965
`
`5,883
`
`3,627
`
`661
`
`122.3%
`
`10,200
`
`4,317
`
`173.4%
`
`Depreciation and amortization
`
`97.2%
`
`998
`
`2,160
`
`903
`
`(95)
`
`90.5%
`
`2,100
`
`(60)
`
`Export volume
`
` Pharmaceuticals
`
` Agrochemicals
`
`5,088
`
`4,231
`
`856
`
`10,137
`
`7,859
`
`2,277
`
`3,438
`
`2,616
`
`822
`
`Employee number
`
`1,475
`
`1,444
`
`1,436
`
`67.6%
`
`61.8%
`
`96.0%
`
`(1,649)
`
`(1,615)
`
`(34)
`
`(39)
`
`6. Breakdown of Non-consolidated Net Sales by Segment
`
`( Figures less than one million yen have been omitted)
`
`FY2015
`2nd Q
`
`FY2015
`
`FY2016
`2nd Q
`
`Y o Y increase(decrease) FY2016
`Forecasts
`
`Yen
`
`%
`
`
`
`Y o Y increase(decrease)Y o Y increase(decrease)
`
`Yen
`
`%
`
`Pharmaceuticals &
`medical devices
`
`Agrochemicals
`
`Renting real estate
`
`50,790
`
`100,062
`
`47,831
`
`(2,958)
`
`94.2%
`
`96,180
`
`(3,882)
`
`96.1%
`
`2,080
`
`981
`
`5,620
`
`1,944
`
`2,384
`
`1,190
`
`304
`
`209
`
`114.6%
`
`121.3%
`
`5,870
`
`2,350
`
`250
`
`406
`
`104.4%
`
`120.9%
`
`Total
`
`53,851
`
`107,627
`
`51,406
`
`(2,445)
`
`95.5% 104,400
`
`(3,227)
`
`97.0%
`
`Note: The Company absorbed and merged with KAKEN REALTY & SERVICE CO., LTD. as of March 31, 2016. Non-consolidated financial
` results for the six-month period of fiscal 2016 include a portion of sales previously recorded at KAKEN REALTY & SERVICE CO.,
` LTD., such as net sales to external customers.
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`3
`
`Page 4 of 5
`
`

`

`7. Breakdown of Sales by Main Pharmaceuticals and Medical Devices
`
`( Figures less than one million yen have been omitted)
`
`FY2015
`2nd Q
`
`FY2015
`
`FY2016
`2nd Q
`
`%
`
`FY2016
`Forecasts
`
`%
`
`15,659
`
`30,760
`
`14,955
`
`95.5%
`
`29,300
`
`95.3%
`
`9,804
`
`19,868
`
`11,639
`
`118.7%
`
`23,800
`
`119.8%
`
`5,641
`
`11,262
`
`5,536
`
`98.1%
`
`11,400
`
`101.2%
`
`2,237
`
`4,526
`
`2,227
`
`99.5%
`
`4,400
`
`97.2%
`
`1,816
`
`3,617
`
`1,846
`
`101.6%
`
`3,700
`
`102.3%
`
`Anti-osteoarthritis
`Artz
`
`Anti-nail fungus
`Clenafin
`
`Post-operative anti-adhesive
`Seprafilm
`
`Anti-hyperlipidemia
`Lipidil
`
`Wound healing agent
`Fiblast Spray
`
`Generic products
`
`6,584
`
`13,292
`
`5,984
`
`90.9%
`
`12,700
`
`95.5%
`
`Sales of Jublia*
`
`3,474
`
`5,722
`
`1,331
`
`38.3%
`
`4,100
`
`71.7%
`
`(*including sales of API and finished product, royalty revenue, milestone revenue and initial payment)
`
`8. Development Status
`
`Code
`
`Indication
`
`Stage
`
`Remarks
`
`KAG-308
`
`Ulcerative colitis
`
`PII
`
`Developed jointly with Asahi Glass Co., Ltd.;
`Oral-use prostaglandin analog
`
`BBI-4000
`
`KMW-1
`
`Primary focal
`hyperhidrosis
`
`Preparing for PII
`
`Removal of eschar with
`thermal burns
`
`Preparing for clinical
`trial
`
`Licensed from Brickell Biotech, Inc.;
`Topical anticholinergic
`
`Licensed from MediWound Ltd.;
`Topically-applied enzymatic product
`Overseas product name : NexoBrid
`
`KAKEN PHARMACEUTICAL CO., LTD.
`
`4
`
`Page 5 of 5
`
`